Abstract: The invention relates to a urea preparation containing (A) 5 to 75 wt. % of one or more urea components which have a molecular weight of at least 350 g/mol and contain at least one urea group; (B) 15 to 95 wt. %, preferably 30 to 80 wt.

Abstract: A coating composition having excellent adhesion between coating layers is provided. This disclosure is particularly directed to a 1K waterborne coating composition having hydrophobic polytrimethylene ether polyol containing crosslinkable functional hydroxyl groups. The 1K waterborne coating composition can be used in a multi-layer coating that can comprise a primer layer, a basecoat layer, and optionally, a clearcoat layer. The 1K waterborne coating composition of this disclosure can provide improved adhesion between coating layers, such as between a primer layer and a basecoat layer, between two or more basecoat layers, or between a basecoat layer and a clearcoat layer. This disclosure is further directed to a coating composition comprising components derived from renewable resources.

Abstract: Compounds of the formula: are disclosed. The compounds act as phosphodiesterase-4 modulators, and useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions. Other embodiments are also disclosed.

Abstract: Provided are improved agricultural processes for the improved cultivation of rice wherein the crops are treated to control undesired vegetative growth using a plant treatment composition comprising both halosulfuron and thifensulfuron to provide improved herbicidal efficacy against Heteranthera limosa, commonly referred to as “duck salad”. Also provided are compositions useful in the improved agricultural processes, as well as herbicidal treatment regimens. Unexpectedly high rates of efficacy against Heteranthera limosa, amongst rice plant in rice crops are disclosed.

Abstract: The present invention relates to carbamoylation of amines, mercaptanes, thiophenols and phenols employing organic azides. More specifically, the invention relates to a method for generating urea derivatives, thiocarbamate derivatives and carbamate derivatives, and is based on the intermediate formation of isocyanate, starting from an organic azide. The reaction as described is useful in applications for modified nucleoside synthesis, oligonucleotide synthesis, as well as modification, labeling and conjugation of polymers and biomolecules.

Abstract: The invention relates to a method for producing oligourea compounds by chain building and depolymerization, and to oligourea dispersions, as well as to their use as fungicides, biocides and/or herbicides.

Abstract: A process for solubilizing hydrophobic active ingredients in aqueous medium, which comprises using, as an assistant, at least one hyperbranched polymer (A) which is obtainable by reacting at least one hyperbranched polymeric compound having at least one primary or secondary amino group per molecule (a), selected from (a1) hyperbranched polyamides and (a2) hyperbranched polyureas, with (b) at least one mono-, di- or oligosaccharide.

Abstract: The present invention relates to the synthesis of lipophilic or immobilized monobasic phosphate (H2PO4) ionophores (7, 8a, 8b and 11) to be used as ion recognition molecules for monobasic phosphate (H2PO4?) in the cocktail preparation of hydrophobic polymer membranes in ion selective electrode (ISE) or ion-sensitive field effect transistor (ISFET) chemical sensors for detection of monobasic phosphate (H2PO4) ionic species in soil, synthetic media, hydrophonic liquid, tree sap, ground water and rivers.

Abstract: A urea compound of the present invention is represented by general formula (I) shown below: wherein each of X1, X2 and X3 independently represents a hydrogen atom, an alkyl group or an aryl group. The aryl group may have one or more functional groups selected from the group consisting of halogen groups, alkyl groups and alkoxy groups.

Abstract: Method of single step electrochemical generation of chlorinated urea, chlorinated dimethylurea and other chlorourea derivatives is disclosed. The chlorinated species are generated in situ and upon demand and can be used for microbial control in industrial water treatment.

Abstract: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.

Abstract: The present invention provides manufacturing of and the use of novel diethylene tricarbamide and its condensation reaction products formed by reacting with formaldehyde as wood composite binder resins and in other applications. These resins have thermosetting capabilities and therefore usefulness as binders for wood and other materials with superior resin properties of low cost, colorlessness, exceptionally good binding, and fast curing characteristics, as well as very low formaldehyde emissions. The synthesized novel starting material for the thermosetting resins of the present invention is diethylene tricarbamide.

Abstract: Provided is a complex of hydrogen peroxide and at least one compound represented by Formula I: wherein X is: —C(R3)3, —C?C(R3), —O(R3), —N(R3)2, or —S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl heteroarylalkyl, heterocyclyl, and cycloalkyl, or R2 and an R3 are optionally taken together to form an alicyclic ring. Also provided are anaerobic cure systems and curable compositions employing the complexes described herein.

Abstract: The invention provides a process for manufacturing biocidal compositions containing bromourea derivatives, including the reaction of salts or adducts of the urea derivatives with an oxidizer.

Abstract: The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11?-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.

Abstract: A urea granulation process and the apparatus suitable for operating that process integrates a method for reducing ammonia emissions from a urea granulation plant which is emitted by a urea production process by scrubbing the off-gas and recovering the scrubber bleed and integrating it into the granulation process so that ammonium salts are completely contained by the process.

Abstract: A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Abstract: A process for urea production from ammonia and carbon dioxide, made to react at a predetermined high pressure in an appropriate synthesis reactor (112), from the reaction between NH3 and CO2 being obtained a reaction mixture comprising urea, ammonium carbamate and free ammonia in aqueous solution, from which a recovery of ammonium carbamate and ammonia is carried out with their subsequent recycle to the synthesis reactor (112), said recovery from the reaction mixture taking place through operative steps of decomposition of the ammonium carbamate into NH3 and CO2 and of their stripping and a subsequent operative step of their recondensation into ammonium carbamate that is recycled to the synthesis reactor, the said reaction mixture obtained from the reaction between ammonia and carbon dioxide being pumped to the operative steps of decomposition and stripping.

Abstract: Process for increasing the capacity of an existing urea plant comprising a high-pressure urea synthesis section and one or more recovery sections, wherein next to the existing urea plant a urea production unit, comprising a high-pressure urea synthesis section and a medium-pressure recovery section, is installed, wherein a urea-containing stream is produced from ammonia and carbon dioxide and the urea-containing stream is sent to the existing urea plant where the urea-containing stream is further purified in the low-pressure recovery section.

Abstract: The gaseous effluent to be treated is contacted in column C1 with an absorbent solution selected for its property of forming two separable phases when it is heated. The regenerated absorbent solution is separated into two phases in drum B1; a fraction rich in water and a fraction rich in reactive compounds. Separation allows to optimize the operations performed on the regenerated absorbent solution. On the one hand, separation allows to carry out vaporization, through reboiler R1, of a fraction of the absorbent solution, preferably containing a limited reactive compound concentration in relation to the absorbent solution, thus limiting their degradation. On the other hand, separation of the phases allows to reduce the amount of solution to be treated in order to remove the non-regeneratable salts and thus to reduce the costs linked with their elimination. Finally, separation allows to eliminate the degradation products by carrying out a specific and suitable purification for each phase.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: The present invention comprises a compound of a compound of Formula 1 wherein Rf is a C2 to C12 perfluoroalkyl optionally interrupted by one to four moieties each independently selected from the group consisting of —CH2—, —O—, —S—, —S(O)—, and —S(O)2—; n is 1 to 6; m is 0 to 2, provided that m is less than or equal to n. X and Y are each independently O or NR, R is hydrogen or C1 to C6 alkyl; R1, and R2 are each independently C1 to C6 alkyl, optionally containing one or more oxygen atoms and may form a ring selected from the group of piperidine, pyrrolidine, and morpholine; and R3 is O?, (CH2)pC(O)O?, (CH2)pCH(OH)(CH2)SO3?, and (CH2)qSO3?; p is 1 to 4; and q is 2 to 4 which is useful as a surfactant.

Abstract: Process for preparing a composition by reacting a polyisocyanate, a monoalkoxy polyoxyalkylene monoamine and water. The composition and its use in making cellular products are claimed as well.

Abstract: Reaction products prepared from reactants including: (a) at least one compound of structural Formula (I): wherein R1 is selected from aryl and heteroaryl; X is selected from a direct bond, —O—, —S—, —NH—, alkylene, cycloalkylene, heterocyclylene, arylene, alkarylene, and heteroarylene; Y is a substituted alkylene group having at least two contiguous carbon atoms and which can be interrupted by one or more —O—, —S—, or —NH— moieties as defined herein, wherein the alkylene group of Y has substituents independently selected from —OH, —NH2, —SH, cycloalkyl, heterocyclyl, aryl, and heteroaryl, or two hydrogen atoms on the same carbon atom of Y are replaced by carbonyl, and wherein at least two substituents of Y are each independently selected from —OH, —NH2, and —SH, as defined herein; and (b) at least one isocyanate functional material.

Abstract: Provided is a complex of hydrogen peroxide and at least one compound represented by Formula I: wherein X is: —C(R3)3, —C?C(R3), —O(R3), —N(R3)2, or —S(R3); and R1, R2, and R3 are each independently selected from H, alkyl, alkenyl, alkynyl, aralkyl, aryl, heteroaryl heteroarylalkyl, heterocyclyl, and cycloalkyl, or R2 and an R3 are optionally taken together to form an alicyclic ring. Also provided are anaerobic cure systems and curable compositions employing the complexes described herein.

Abstract: A novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C is disclosed. The therapeutic agent for hepatitis C contains as an effective ingredient hydroxyurea. The therapeutic agent for hepatitis C optionally further contains interferon ?. By the present invention, a novel therapeutic agent for hepatitis C having a high therapeutic effect against hepatitis C was provided. A synergistic therapeutic effect against hepatitis C is obtained by using interferon ? in combination. Therefore, in cases where a patient is infected with the genotype of hepatitis C virus for which therapy by interferon ? is effective, the therapeutic effect is further promoted by using interferon ? in combination.

Abstract: Dendritic or hyperbranched polyurethanes are prepared by 1) reacting diols or polyols having at least one tertiary nitrogen atom and at least two hydroxyl groups of differing reactivity toward isocyanate groups with diisocyanates or polyisocyanates to form an addition product, with the diols or polyols and diisocyanates or polyisocyanates being selected so that the addition product has, on average, one isocyanate group and more than one hydroxyl group or one hydroxyl group and more than one isocyanate group, 2) converting the addition product from step 1) into a polyaddition product by intermolecular reaction of the hydroxyl groups with the isocyanate groups, and with a reaction with a compound containing at least two hydroxyl groups, mercapto groups, amino groups or isocyanate groups also being able to be carried out first, 3) if desired reacting the polyaddition product from step 2) with a compound containing at least two hydroxyl groups, mercapto groups, amino groups or isocyanate groups.

Abstract: The present invention comprises a method for controlling (e.g. inhibiting) or killing microorganisms in an aqueous environment. The method includes the addition of an effective amount of monochlorourea or modified monochlorourea to an aqueous solution. This aqueous solution may be a cooling water system, a recreational water system, a water treatment facility, or any circulating water system (i.e. a papermaking facility). A method of producing monochlorourea or modified monochlorourea is also disclosed.

Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.

Abstract: The invention provides novel classes of HDAC inhibitors. Methods of sensitizing a cancer cell to the cytotoxic effects of radiotherapy are also provided as well as methods for treating cancer and methods for treating neurological diseases. Additionally, the invention further provides pharmaceutical compositions comprising an HDAC inhibitor of the invention, and kits comprising a container containing an HDAC inhibitor of the invention.

Abstract: This invention relates to a novel process for the synthesis of Temozolomide, an antitumor compound, and analogs, and to intermediates useful in this novel process.

Abstract: Compounds of the formula or a pharmaceutically acceptable salt thereof or a tautomer thereof, wherein A and B are as described herein, are useful for treating conditions afflicting mammals.

Abstract: The present invention relates to carbamoylation of amines, mercaptanes, thiophenols and phenols employing organic azides. More specifically, the invention relates to a method for generating urea derivatives, thiocarbamate derivatives and carbamate derivatives, and is based on the intermediate formation of isocyanate, starting from an organic azide. The reaction as described is useful in applications for modified nucleoside synthesis, oligonucleotide synthesis, as well as modification, labeling and conjugation of polymers and biomolecules.

Abstract: The present invention relates to a production method of optically active hydrazine compound (IV), which includes reacting azo compound (II) with compound (III) in the presence of optically active compound (I). The present invention also relates to a production method of optically active amine compound (V), which includes producing optically active hydrazine compound (IV) by the above-mentioned method, reacting the optically active hydrazine compound (IV) with a base or an acid to eliminate a protecting group represented by PG, and then subjecting the resulting compound to catalytic reduction or reacting the resulting compound with a zinc powder to reduce a nitrogen-nitrogen bond. wherein X is S or O; C*, C** and C*** are asymmetric carbons, R1 and R2 are lower alkyl groups etc., R4 and R5 may in combination form cyclohexane etc., R3 is aryl group optionally having substituent(s) etc., R6 and R7 are hydrogen atoms etc., R8 is aryl group optionally having substituent(s) etc.

Abstract: This invention relates to novel aryl ureido benzoic acid derivatives useful as selective and non-competitive antagonists of the ionotropic GluR5 receptor. Due to their biological activity, the aryl ureido derivatives of the invention are considered useful for treating diseases that are responsive to modulation of an aspartate or a glutamate receptor. Moreover the invention provides chemical compounds for use according to the invention, as well as pharmaceutical compositions comprising the chemical compounds, and methods of treating diseases or disorders or conditions responsive to modulation of an aspartate or a glutamate receptor.

Abstract: (Per)haloethers having formula: X-(Rf)L-O—CF2CF2—O—CX1X2—CFX3X4 , ??(I) process for obtaining them and hypofluorites usable in the synthesis of said (per)haloethers.

Abstract: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. They have the general formula (I) in which R1 represents hydrogen or C1-6 alkyl, and X represents —N(H)Y1, —(H)—C1-6 alkyleneY1, biphenyl or C1-6 alkyl substituted by biphenyl, and the group Y1 is an optionally substituted biphenyl. The tetrahydro-naphthalene derivatives of the present invention have excellent activity as VR1 antagonists and are useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, overactive bladder, urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.

Abstract: The present invention is directed to blocked biuret group-containing polyisocyanate compositions, wherein the blocking agent is of the formula: wherein R1, R2, R3 and R4 may be the same or different and represent a moiety selected from the group consisting of hydrogen, C1-C6-alkyl and C3-C6-cycloalkyl, R5 represents a moiety selected from the group consisting of C1-C10-alkyl and C3-C10-cycloalkyl, and B is a group according to one of the following structural formulas wherein each occurrence of R6, R7, and R8 may be the same or different and represent a moiety selected from the group consisting of C1-C6-alkyl and C3-C6-cycloalkyl and R9 is a moiety selected from the group consisting of hydrogen, C1-C6-alkyl and C3-C6-cycloalkyl.

Abstract: High-functionality polyisocyanates are prepared by a process which comprises (i) preparation of an addition product (A) which contains one group which is reactive toward isocyanate and at least two isocyanate groups by reacting (a) a diisocyanate or polyisocyanate I with (b1) compounds having at least three groups which are reactive toward isocyanate or (b2) compounds containing two groups which are reactive toward isocyanate or mixtures of (b1) and (b2), where at least one of the components (a) or (b) has functional groups having differing reactivities toward the functional groups of the other component and the reaction ratio is selected so that the addition product (A) contains an average of one group which is reactive toward isocyanate, (ii) if desired, intermolecular addition reaction of the addition product (A) to form a polyaddition product (P) containing an average of one group which is reactive toward isocyanate and an average of more than two isocyanate groups, and (iii) reaction of the addition

Abstract: Thermoreversible organogelator compositions comprising compounds of the formula: where X is C6 to C12 alkylene and R is C9 to C12 alkyl, and their methods of use, including forming a gel to immobilize a solvent using the compound. The method can be used to form gels that can be used for the transportation of volatile organic solvents like gasoline, cooking oil, and contaminated organic liquids to be incinerated.

Abstract: Electron donor compounds, suitable for use as adhesives or as components in adhesives, contain a carbon to carbon double bond attached to an aromatic ring and conjugated with the unsaturation in the aromatic ring.

Abstract: The present invention concerns a process for producing low-viscosity polyisocyanates or secondary products thereof, which carry activated, radiation-curable double bonds and can optionally also cure thermally, and low-viscosity polyisocyanate mixtures or secondary products thereof and their use in coating compounds.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: An additive for an alkaline zinc or zinc alloy electroplating bath medium, the additive comprising a random co-polymer comprising the reaction product of: (i) one or more di-tertiary amines including an amide or thioamide functional group, and (ii) optionally, one or more saturated second di-tertiary amines and/or one or more second di-tertiary amines including an unsaturated moiety, with (iii) one or more saturated or unsaturated linking agents capable of reacting with said di-tertiary amines (i) and (ii), provided that, where all the linking agents are saturated, an unsaturated di-tertiary amine must he present. Preferably, the polymer has the general formula n(2x+2y+zEp)j-.

Abstract: Blocked polyisocyanates and one-component stoving systems containing these blocked polyisocyanates, and the preparation thereof and their use for the preparation of lacquers, paints, adhesives and elastomers, wherein blocked polyisocyanates are prepared by reacting polyisocyanates with secondary amines corresponding to the formula wherein R1—R4 can be identical or different and denote hydrogen, C1–C6-alkyl or cycloalkyl, R5 denotes C1–C10-alkyl, C3–C10-cycloalkyl, y denotes a number from 2 to 8, and B represents wherein R6–R8 can be identical or different and independently of one another denote C1–6-alkyl and/or C3–C6-cycloalkyl, R9 denotes hydrogen or C1–6-alkyl or C3–C6-cycloalkyl.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: The present invention relates to thiourea compounds and the pharmaceutical compositions containing the same, and particularly, to novel thiourea compounds as an antagonist against vanilloid receptor (VR) and the pharmaceutical compositions thereof. As diseases associated with the activity of vanilloid receptor, pain, acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflammatory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.

Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Abstract: A blocked polyisocyanate adduct including 5 to 95% by weight of at least one isocyanate component having at least one NCO group, the isocyanate component selected from the group consisting of aliphatic, cycloaliphatic and aromatic isocyanates, wherein the isocyanate has an average molecular weight of up to 1000 g/mol and an average NCO functionality of 2–4; 5 to 70% by weight of at least one hydrophilicizing component containing at least one group which is reactive toward the at least one NCO group; at least one blocking agent for blocking from 95 to 100% of the NCO groups which do not react with the hydrophilicizing component; and up to 15% by weight of at least one neutralizing agent.

Abstract: Compounds of formula (I) wherein the groups are as defined in the description are disclosed. The compounds of formula (I) are endowed with reversible inhibiting activity of carnitine palmitoyl-transferase and are useful in the preparation of medicaments useful in the pathologies related to a hyperactivity of carnitine palmitoyl-transferase, such as hyperglycemia, diabetes and pathologies related thereto, heart failure, ischemia.